Contemporary Considerations for Breast Cancer Risk and Screening in Transgender, Nonbinary, and Gender-Diverse Populations.

IF 1 Q4 ONCOLOGY

Current Breast Cancer Reports Pub Date : 2025-01-01 Epub Date: 2025-02-13 DOI:10.1007/s12609-025-00573-6

Victoria Huynh, Meghan Conroy, Evelyn F Carroll, Chandler S Cortina

{"title":"Contemporary Considerations for Breast Cancer Risk and Screening in Transgender, Nonbinary, and Gender-Diverse Populations.","authors":"Victoria Huynh, Meghan Conroy, Evelyn F Carroll, Chandler S Cortina","doi":"10.1007/s12609-025-00573-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: Breast cancer incidence, risk factors, and risk-reducing strategies are relatively well established for cisgender persons, but this information is limited in the transgender and gender-diverse (TGD) community. TGD persons have unique considerations that may affect risk, such as the need for gender-affirming hormone therapy or gender-affirming operations. This review outlines key literature informing our knowledge of breast cancer risk and summarizes screening recommendations for TGD persons.Recent findings: Studies informing breast cancer risk in TGD persons have significant limitations. Generally, they suggest that transgender women have a higher incidence of developing breast cancer compared to cisgender men, but a much lower incidence compared to cisgender women; and that transgender men have higher rates of breast cancer compared to cisgender men, but lower rates compared to cisgender women. Screening guidelines put forth by professional societies are based on these retrospective cohort studies, expert consensus, and extrapolation from cisgender populations. The United States Preventive Services Task Force and American Cancer Society have not yet published guidelines.Summary: Prospective data are needed to further define risk and best practices for breast cancer screening in the TGD community, an already marginalized population susceptible to worse oncologic outcomes.","PeriodicalId":10769,"journal":{"name":"Current Breast Cancer Reports","volume":"17 ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234010/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Breast Cancer Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12609-025-00573-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Breast cancer incidence, risk factors, and risk-reducing strategies are relatively well established for cisgender persons, but this information is limited in the transgender and gender-diverse (TGD) community. TGD persons have unique considerations that may affect risk, such as the need for gender-affirming hormone therapy or gender-affirming operations. This review outlines key literature informing our knowledge of breast cancer risk and summarizes screening recommendations for TGD persons.

Recent findings: Studies informing breast cancer risk in TGD persons have significant limitations. Generally, they suggest that transgender women have a higher incidence of developing breast cancer compared to cisgender men, but a much lower incidence compared to cisgender women; and that transgender men have higher rates of breast cancer compared to cisgender men, but lower rates compared to cisgender women. Screening guidelines put forth by professional societies are based on these retrospective cohort studies, expert consensus, and extrapolation from cisgender populations. The United States Preventive Services Task Force and American Cancer Society have not yet published guidelines.

Summary: Prospective data are needed to further define risk and best practices for breast cancer screening in the TGD community, an already marginalized population susceptible to worse oncologic outcomes.

查看原文本刊更多论文

当代对跨性别、非二元和性别多样化人群乳腺癌风险和筛查的考虑。

综述目的：乳腺癌的发病率、危险因素和降低风险的策略在顺性人群中是相对完善的，但在跨性别和性别多样化（TGD）人群中这方面的信息是有限的。TGD患者具有可能影响风险的独特考虑因素，例如需要进行性别确认激素治疗或性别确认手术。这篇综述概述了重要的文献，使我们了解乳腺癌的风险，并总结了对TGD患者的筛查建议。最新发现：关于TGD患者乳腺癌风险的研究有明显的局限性。总的来说，他们认为变性女性患乳腺癌的几率比顺性男性高，但比顺性女性低得多；变性男性患乳腺癌的几率比顺性男性高，但比顺性女性低。专业协会提出的筛查指南是基于这些回顾性队列研究、专家共识和顺性别人群的推断。美国预防服务工作组和美国癌症协会尚未公布指南。总结：需要前瞻性数据来进一步确定TGD社区乳腺癌筛查的风险和最佳实践，TGD社区是一个已经边缘化的人群，容易出现更差的肿瘤结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Breast Cancer Reports ONCOLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of breast cancer. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those with the disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as prevention, systemic therapy, and translational research. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.